Podcasts about tarceva

Dr. John LaMattina, Ph.D. (https://www.johnlamattina.com), is an independent non-executive director at PureTech, a biotechnology company with a mission to discover, develop and commercialize new therapies for devastating diseases, where limited or no treatment options currently exist for patients, and has served as a member of their board of directors since 2009. Dr. LaMattina was previously President of Pfizer Global Research and Development and held positions of increasing responsibility during his 30-year career at Pfizer, including vice president of US Discovery Operations in 1993, senior vice president of Worldwide Discovery Operations in 1998 and senior vice president of Worldwide Development in 1999. During Dr. LaMattina's leadership tenure, Pfizer discovered and/or developed a number of important new medicines including Tarceva, Chantix, Zoloft, Selzentry and Lyrica, along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain. Dr. LaMattina serves on the board of directors of Ligand Pharmaceuticals, Zafgen, Inc., Immunome Inc. and Vedanta Biosciences, Inc. He also serves on the Scientific Advisory Board of Frequency Therapeutics and is a trustee associate of Boston College. Dr. LaMattina is the author of numerous scientific publications and US patents. In addition, Dr. LaMattina is the author of the recently released Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices (https://www.amazon.com/Pharma-Profits-Balancing-Innovation-Medicine-ebook/dp/B0B33V6B7Y), as well as Devalued and Distrusted: Can the Pharmaceutical Industry Restore Its Broken Image, Drug Truths: Dispelling the Myths About Pharma R&D, and an author of the Drug Truths blog at Forbes.com (https://www.forbes.com/sites/johnlamattina/?sh=4ea8dc042b0d). Dr. LaMattina was awarded an Honorary Doctor of Science degree from the University of New Hampshire in 2007 and in 2010 was the recipient of the American Chemical Society's Earle B. Barnes Award for Leadership in Chemical Research Management. Dr. LaMattina received a BS in chemistry from Boston College in 1971 and received a PhD in organic chemistry from the University of New Hampshire in 1975. He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor.

In November of 2012, shortly after Dawn was diagnosed with stage IV lung cancer, she learned that her cancer had the vulnerable EGFR mutation. In her new book titled Winded: A Memoir in Four Stages, Dawn writes about living life to the fullest after being diagnosed with stage IV lung cancer. She has been treated with the drug Tarceva for close to eight years and she writes unflinchingly but with great tenderness about both her cancer fight and her struggle with depression. This is a worthwhile read for anyone who has ever struggled with depression, cancer or a chronic illness and it is also a worthwhile read for the people close to that person. --- Support this podcast: https://anchor.fm/griefandrebirth/support

In November of 2012, shortly after Dawn was diagnosed with stage IV lung cancer, she learned that her cancer had the vulnerable EGFR mutation. In her new book titled Winded: A Memoir in Four Stages, Dawn writes about living life to the fullest after being diagnosed with stage IV lung cancer. She has been treated with the drug Tarceva for close to eight years and she writes unflinchingly but with great tenderness about both her cancer fight and her struggle with depression. This is a worthwhile read for anyone who has ever struggled with depression, cancer or a chronic illness and it is also a worthwhile read for the people close to that person. --- Support this podcast: https://anchor.fm/griefandrebirth/support

We are continuing our conversation with Dr. Paula O'Connor and delving into the role of pharma in access to medicine and clinical trials. Dr. O'Connor goes over the safety measures in place to keep patients safe throughout a trial and how clinical trials can give access to novel drugs to patients who may not otherwise be able to afford them.About Dr. Paula O'ConnorDr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.  Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.--New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com  A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients. Learn more about Oncopeptides at https://www.oncopeptides.com/en Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

We are so excited for this next episode with our special guest, Dr. Paula O'Connor! We talk about finding your path in medicine and all of the many opportunities there are to follow your passions within the medical field. Dr. O'Connor gave us so many gems development of career and development of self.About Dr. Paula O'ConnorDr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.  Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.--New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com  A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients. Learn more about Oncopeptides at https://www.oncopeptides.com/en Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

Lorna Main is a nursing thought leader in the UK, teaches nursing at the University of Greenwich and is completing a doctorate.Scientific papers referenced (and relevant) in the podcast:Bowles, N. (1995) Story telling: a search for meaning within nursing practice Nurse, Education Today (15) 365-369Creswell, J.W. (2014) Research Design. Qualitative, Quantitative and Mixed Methods Approaches 4 th Ed. Sage Publications. LondonCrotty, M. (1998) The Foundations of Social Research Meaning and perspective in the research process. Sage Publications. LondonDenscombe, M. (2014) The Good Research Guide for small scale social research projects 5 th Ed. Open University Press. UKGerrish, K. and Lacey, A. (2010) The Research Process in Nursing 6 th Ed. Wiley –Blackwell. UK.Gillard, S., Borschmann, R., Turner, K., Goodrich-Purnell, N., Lovell, K., and Chamber, M. (2011) Producing different analytical narratives, coproducing integrated analytical narrative: a qualitative study of UK detained mental health patient experience involving service user researchers International Journal of Social Research Methodology. http://www.tandfonline.com/loi/tsrm20 (Last accessed 7/7/2018)Haigh, C. and Hardy, P. (2011) Tell me a story – a conceptual exploration of storytelling in healthcare education. Nurse Education Today (31) 408-411Hart, C. (2014) Doing a Literature Review, Releasing the Social Sciences, Research imagination. Sage Publications. U.K.Jordens, C.F.C. and Little, M. (2004) ‘In this scenario, I do this, for these reasons’: narrative, genre and ethical reasoning in the clinic. Social Science & Medicine, May 1635–1645Lazzerfield-Jensen, A. (2014) Telling stories out of school: Experiencing the paramedic’s oral traditions and role dissonance Nurse Education in Practice (14) 734-739Nursing and Midwifery Council (NMC) (2018) The Code. NMC publications. London https://www.nmc.org.uk/standards/code/ (Accessed 7/7/2018)Ohnsorge, K., Keller, H.R., Widdershoven G.A.M., Sutter, C.R. (2012) ‘Ambivalence’ at the end of life: How to understand patients’ wishes ethically Nursing Ethics 19(5) 629–641Ouyang, W.C. (2004) Genres, ideologies, genre ideologies and narrative transformation, Middle Eastern Literatures (7) 2, 125-131Rorty, A. (1996) Essays on Aristotle's Rhetoric Berkeley, Univ. of Calif. Press.Smith, S.M., Soubhi, H., Fortin, M., Hudon, C., O’Dowd, T. (2012) Managing patients with multimorbidity: systematic review of interventions in primary care and community settings British Medical Journal 345:e5205 doi: 10.1136/bmj.e5205Walter, L.C. and Covinsky, K.E. (2001) Cancer Screening in Elderly Patients A Framework for Individualized Decision Making. http://jamanetwork.com/journals/jama/article-abstract/193893 (Accessed 6/7/2018)

Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva) with bevacizumab (Avastin), which shows a consistent improvement in progression-free survival but not overall survival.

Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.

MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.

MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.

Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.

Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.

Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.

Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.

Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.

Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.

Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.

Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.

Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.

Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.

Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.

Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.

The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.

The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.

The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.

A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.